Today's Top Performers In Health Services

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 78 points (0.5%) at 17,023 as of Friday, Sept. 26, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,765 issues advancing vs. 1,183 declining with 200 unchanged.

The Health Services industry currently is unchanged today versus the S&P 500, which is up 0.3%. A company within the industry that fell today was Agilent Technologies ( A), up 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. St Jude Medical ( STJ) is one of the companies pushing the Health Services industry higher today. As of noon trading, St Jude Medical is up $0.69 (1.1%) to $61.59 on light volume. Thus far, 446,705 shares of St Jude Medical exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $61.10-$61.72 after having opened the day at $61.26 as compared to the previous trading day's close of $60.90.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

St. Jude Medical, Inc. develops, manufactures and distributes medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. St Jude Medical has a market cap of $17.7 billion and is part of the health care sector. Shares are down 1.3% year-to-date as of the close of trading on Thursday. Currently there are 15 analysts who rate St Jude Medical a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full St Jude Medical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Can Abbott Outperform Despite Alere?

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Labs: Diagnosing Growth in 2017

Abbott Laboratories Can Merge With St. Jude Medical: FTC

FTC Allows Abbott to Spin Off Units, Buy St. Jude Medical